News Hub

Real-time financial, economic, and global news with market-focused context and analysis.

Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.

  • No major market-moving headlines published in the past hour.
  • No central bank statements or policy actions were released.
  • No high-impact economic data or corporate earnings were reported.
  • No major geopolitical incidents or sanction announcements occurred.
  • No significant regulatory or legal rulings affecting markets were reported.
  • Markets are operating without fresh news catalysts for immediate repricing.

Latest Articles

Plug and Arcadia eFuels Sign Strategic Partnership Covering More Than 1 GW of e-SAF Projects, Starting with 280 MW to Turn Danish Renewable Electricity into Jet Fuel

Plug and Arcadia eFuels Sign Strategic Partnership Covering More Than 1 GW of e-SAF Projects, Starting with 280 MW to Turn Danish Renewable Electricity into Jet Fuel

Plug Power Inc. has signed a 280 MW electrolyzer supply agreement with Arcadia eFuels for Project ENDOR in Denmark, alongside a strategic cooperation agreement to become the preferred electrolyzer supplier for more than 1 GW of upcoming e-Sustainable Aviation Fuel (e-SAF) projects across Europe and the Americas. Project ENDOR will convert renewable…

CDT Highlights Sarborg’s Expanding Quantum Computing IP Portfolio and Application to Drug Discovery

CDT Highlights Sarborg’s Expanding Quantum Computing IP Portfolio and Application to Drug Discovery

CDT Equity Inc., a US-listed biopharmaceutical company, announced Sarborg Limited's filing of new intellectual property using quantum computing for drug discovery by targeting disease biology. Sarborg's approach leverages quantum sampling to analyze complex disease gene regulation, advancing beyond traditional methods. The technology shows promise …

GDEV announces preliminary results of previously announced self tender offer to purchase for cash up to $20,000,000 in value of its ordinary shares (or up to 1,813,236 Ordinary Shares) at a purchase price of $11.03 per ordinary share

GDEV announces preliminary results of previously announced self tender offer to purchase for cash up to $20,000,000 in value of its ordinary shares (or up to 1,813,236 Ordinary Shares) at a purchase price of $11.03 per ordinary share

GDEV Inc. disclosed preliminary results of its self-tender offer to buy up to $20 million worth of its ordinary shares at $11.03 per share. Only approximately 56,830 shares (about 0.3% of outstanding shares) were tendered, far below the maximum amount the company aimed to repurchase. The shares purchased will be held as treasury shares. Final purch…

Scorpio Tankers Inc. Announces Agreements to Sell Three Product Tankers and Purchase Four Newbuilding Vessels

Scorpio Tankers Inc. Announces Agreements to Sell Three Product Tankers and Purchase Four Newbuilding Vessels

Scorpio Tankers Inc. announced agreements to sell three older product tankers and purchase four newbuilding vessels, including scrubber-fitted LR2 product tankers and VLCCs, with deliveries planned between 2028 and 2029. This fleet renewal aims to improve operational efficiency and position the company competitively in marine petroleum transportati…

Equinox Gold Reports Continued Exploration Success Along the Musselwhite Mine Trend and Advances New Minotaur Discovery at Valentine

Equinox Gold Reports Continued Exploration Success Along the Musselwhite Mine Trend and Advances New Minotaur Discovery at Valentine

Equinox Gold provided an exploration update highlighting significant drilling results at its Canadian operations, particularly at Musselwhite, Valentine, and Greenstone gold mines. The company continues to see mineral resource growth and potential mine life extensions supported by ongoing drilling programs and plans for processing capacity expansio…

Akamai Welcomes SoftServe to Partner Connect Program

Akamai Welcomes SoftServe to Partner Connect Program

Akamai announced that SoftServe, a digital engineering and AI technology services company, has joined its Partner Connect program. The partnership aims to help enterprises optimize multicloud environments, reduce infrastructure costs, and accelerate edge AI deployments by combining SoftServe's AI expertise and cloud solutions with Akamai's global c…

TransUnion Extends 99-Cent Mortgage Pricing for VantageScore® 4.0 Through the End of 2028 to Support Competition and Price Stability in Mortgage Credit Scoring

TransUnion Extends 99-Cent Mortgage Pricing for VantageScore® 4.0 Through the End of 2028 to Support Competition and Price Stability in Mortgage Credit Scoring

TransUnion announced it will continue offering the VantageScore 4.0 mortgage credit score at $0.99 per origination through December 2028, providing pricing stability and supporting wider adoption among lenders. This extension follows regulatory expansions allowing greater use of VantageScore 4.0 by Fannie Mae, Freddie Mac, and FHA, enhancing credit…

Credit Card Application Fraud Climbs as Identity Thieves Disproportionately Target Canadians Aged 56 to 65

Credit Card Application Fraud Climbs as Identity Thieves Disproportionately Target Canadians Aged 56 to 65

Equifax Canada's latest Market Pulse reveals a notable 8% year-over-year increase in credit card application fraud in Q2 2026, primarily due to third-party identity theft. The fraud rise contrasts declines in auto, mortgage, and telecom applications. Canadians aged 56-65 are disproportionately targeted, exploiting their higher credit limits and les…

ThredUp Expands Into Live Shopping with Whatnot

ThredUp Expands Into Live Shopping with Whatnot

ThredUp announced its expansion into the live shopping market by launching live shows on Whatnot, the leading live commerce platform across the US, UK, and Europe. Starting from its distribution centers in Atlanta and Dallas, ThredUp aims to tap into the $22 billion live shopping market by offering millions of curated secondhand fashion items. The …

Nike's Turnaround Is a Time Arbitrage - Buy for the 180-Day Rebound

Nike's Turnaround Is a Time Arbitrage - Buy for the 180-Day Rebound

Nike is trading like a legacy retailer rather than a market-leading brand. With a market cap near $54B, a 4.6% dividend yield, positive free cash flow and a management plan to stabilize inventory and rebuild wholesale relationships, the stock offers an attractive risk-reward for investors willing to wait. This trade idea lays out an entry at $36.50…

Astellas Pact Validates Vir's Platform - Buy for a Mid-Term Re-Rate

Astellas Pact Validates Vir's Platform - Buy for a Mid-Term Re-Rate

Astellas' $315M deal and an advancing oncology and hepatitis delta program give Vir Biotechnology a clearer path to value realization. With a $1.78B market cap, a healthy cash cushion and upcoming Phase 3 readouts, the setup favors a mid-term long trade. Entry $10.75, target $14.00, stop $9.00; horizon: mid term (45 trading days).

Buying Oracle After the AI Capex Shock - A Tactical Long at $132.72

Buying Oracle After the AI Capex Shock - A Tactical Long at $132.72

Oracle is trading roughly 59% below its 52-week high despite strong cloud revenue growth, a $600B+ backlog and improving profitability. The market is punishing heavy capex and negative free cash flow today; that creates a tactical long opportunity around $132.72 with defined stops and staged targets across 10- to 180-trading-day horizons.

Caspian Therapeutics Unveils KO-7246 at EASD as a Potential Best-In-Class Menin Inhibitor for Diabetes

Caspian Therapeutics Unveils KO-7246 at EASD as a Potential Best-In-Class Menin Inhibitor for Diabetes

Caspian Therapeutics and Kura Oncology announced preclinical data for KO-7246, a selective menin inhibitor that promotes beta-cell regeneration, durable glycemic control, and increased endogenous insulin production in Type 1 and Type 2 diabetes models. The compound shows potential as a disease-modifying therapy, complementing existing treatments li…